This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| N-351 | |
|---|---|
| Name | N-351 |
N-351 is a designation applied in technical literature to a specific synthetic organic compound used in research and industrial settings. First characterized in laboratory reports, N-351 has been investigated across diverse contexts including pharmacology, agrochemistry, and materials science. Studies have linked its structure and reactivity to analogs reported in patent filings and academic journals from institutions such as Massachusetts Institute of Technology, Stanford University, University of Cambridge, University of Oxford, and California Institute of Technology.
N-351 is described by systematic and common identifiers provided in filings at databases maintained by Chemical Abstracts Service, PubChem, and ChemSpider. Its nomenclature appears in patent literature associated with organizations like DuPont, BASF, Syngenta, Monsanto (now part of Bayer), and contract research organizations collaborating with Pfizer, Merck & Co., Novartis, and Roche. Structural analogs are compared against standards used by International Union of Pure and Applied Chemistry and characterized using spectroscopy methods developed at facilities such as National Institute of Standards and Technology and European Molecular Biology Laboratory.
Reported synthetic routes to N-351 trace back to methodologies employed in laboratories at University of California, Berkeley, Harvard University, Yale University, ETH Zurich, and Ecole Polytechnique. Typical approaches adapt protocols from palladium-catalyzed cross-coupling reactions popularized by work at Columbia University and University of Tokyo, and from nucleophilic substitution sequences taught in texts by authors affiliated with Princeton University and Johns Hopkins University. Production-scale processes cited in industrial patents reference facilities run by ExxonMobil, Shell, TotalEnergies, and specialty chemical manufacturers such as Sigma-Aldrich (now part of Merck Group), often invoking green-chemistry optimizations inspired by initiatives at United Nations Environment Programme and Green Chemistry Institute.
Characterization data reported by analytical groups at Argonne National Laboratory, Lawrence Berkeley National Laboratory, Brookhaven National Laboratory, and Oak Ridge National Laboratory indicate N-351 exhibits spectral features assignable by techniques developed at Royal Society of Chemistry and instrumentation supplied by Bruker, Agilent Technologies, and Thermo Fisher Scientific. Thermal behavior parallels profiles published in thermochemical compilations associated with American Chemical Society and Royal Dutch Chemical Society. Crystallographic analyses referencing beamlines at European Synchrotron Radiation Facility and Advanced Photon Source compare unit-cell parameters with databases curated by Cambridge Crystallographic Data Centre.
Biological investigations conducted at National Institutes of Health, Centers for Disease Control and Prevention, Food and Drug Administration, and university laboratories including University of Pennsylvania, Columbia University Medical Center, and Stanford School of Medicine explore N-351 interactions with biomolecular targets identified through platforms developed at Broad Institute and Scripps Research. Mode-of-action studies draw on assays standardized by World Health Organization reference centers and utilize computational models from groups at Duke University, Imperial College London, and University of Toronto. Comparisons are often made to pharmacophores studied in programs at Eli Lilly and Company, AstraZeneca, and GlaxoSmithKline.
Applications reported for N-351 span sectors represented by institutions such as United States Department of Agriculture, European Commission, United Nations Industrial Development Organization, and corporate R&D divisions at IBM Research and Siemens. Uses described in patent filings filed at national offices including the United States Patent and Trademark Office, European Patent Office, Japan Patent Office, and China National Intellectual Property Administration cover roles in formulations, catalysts, and intermediates for syntheses reported in collaborations with Bell Labs and Hitachi. Academic case studies from Massachusetts General Hospital, Mayo Clinic, and Cleveland Clinic evaluate translational prospects.
Toxicological profiles have been assessed by toxicology units at National Toxicology Program, European Chemicals Agency, Health Canada, and laboratories affiliated with Karolinska Institutet and Pasteur Institute. Environmental fate studies conducted in collaboration with United Nations Environment Programme, World Wildlife Fund, and monitoring networks coordinated by Environmental Protection Agency examine persistence, bioaccumulation, and ecotoxicity using protocols from Organisation for Economic Co-operation and Development and analytical standards from International Organization for Standardization. Risk assessments cite exposure scenarios evaluated in reports by United Nations Children's Fund and World Bank projects.
Regulatory considerations for N-351 are incorporated into compliance frameworks overseen by Environmental Protection Agency, European Chemicals Agency, Food and Drug Administration, Occupational Safety and Health Administration, and national regulatory authorities such as Medicines and Healthcare products Regulatory Agency and Pharmaceuticals and Medical Devices Agency. Handling and transport guidelines align with standards published by International Air Transport Association, International Maritime Organization, and National Fire Protection Association. Safety data sheets follow formats influenced by Globally Harmonized System of Classification and Labelling of Chemicals.
Category:Chemical compounds